Table 2. Summary of the published literature on the role of epidermal growth factor receptor (EGFR) inhibitors in the management of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
CRT: chemoradiotherapy; GP: Gemcitabine and paclitaxel; IMRT: intensity-modulated radiotherapy; mon: month; NR: not reported; ORR: objective response rate including partial and complete responses; OS: overall survival; PFS: progression-free survival; Ref: reference; Retro: retrospective cohort study; TPF: docetaxel, cisplatin, and 5-fluorouracil; TTP: time to progression
| Ref | Authors | Year | Phase | Country | Patient number | Regimen | ORR (%) | Median TTP (mon) | Median PFS (mon) | Median OS (mon) | One-year PFS (%) | One-year OS (%) |
| [28] | Chan et al. | 2005 | II | China | 60 | Cetuximab + carboplatin | 11.7 | 2.9 | NR | 8.3 | NR | NR |
| [29] | Chua et al. | 2008 | II | China | 19 | Gefiinib | 0 | 4 | NR | 16 | NR | NR |
| [30] | Ma et al. | 2008 | II | China | 16 | Gefitinib | 0 | 2.7 | NR | 12 | NR | NR |
| [31] | You et al. | 2012 | II | Canada | 20 | Erlotinib after six cycles of GP | 0 | 6.9 | NR | Not reached | NR | NR |
| [32] | Xu et al. | 2016 | Retro | China | 30 | Cetuximab + CRT | 70 | 12.2 | NR | 23.6 | NR | NR |
| [33] | Ng et al. | 2018 | II | China | 33 | Neoadjuvant TPF + maintenance docetaxel and cetuximab + IMRT | 30.8 | NR | NR | NR | NR | NR |